Cohen Aubart et al. further recommend considering targeted MEK inhibitor therapies for refractory or disabling cases of CNS-RDD, especially those with MAPK pathway alterations [9]. The gene discussed is MAP2K7; the disease is sinus histiocytosis with massive lymphadenopathy.